MedStar Authors catalog › Details for: Embolic ST-elevation Myocardial Infarction from Candida Endocarditis.
Normal view MARC view ISBD view

Embolic ST-elevation Myocardial Infarction from Candida Endocarditis.

by Ghazzal, Amre; Gill, Gauravpal S; Radwan, Sohab; Barnett, Christopher F.
Citation: Cureus. 12(4):e7833, 2020 Apr 25..Journal: Cureus.Published: ; 2020ISSN: 2168-8184.Full author list: Ghazzal A; Gill GS; Radwan S; Barnett C.UI/PMID: 32467808.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar Heart & Vascular Institute | MedStar Washington Hospital CenterDepartment(s): Medicine/Internal MedicineActivity type: Journal Article.Medline article type(s): Case ReportsOnline resources: Click here to access online Digital Object Identifier: https://dx.doi.org/10.7759/cureus.7833 (Click here) Abbreviated citation: Cureus. 12(4):e7833, 2020 Apr 25.Abstract: Infective endocarditis in intravenous drug users is uncommon in left-sided native valves. Adding to the rarity, in this case, is endocarditis from Candida species complicated by ST-elevation myocardial infarction. Embolic myocardial infarction has worse outcomes as compared to other etiologies, and the management of septic embolic myocardial infarction is rather challenging. The management of embolic myocardial infarction from Candida endocarditis vegetation includes antifungal therapy. The use of anti-thrombotic therapy and anticoagulation carries a significant risk of fatal neurologic complications and has been controversial, with limited observational data available. Among percutaneous coronary interventions, balloon angioplasty and stenting have been associated with multiple complications while aspiration embolectomy appears to be a safer option. Surgical management is considered if medical and interventional therapies fail or if there is an indication for valve replacement. Copyright (c) 2020, Ghazzal et al.

Powered by Koha